We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02020317
First Posted: December 24, 2013
Last Update Posted: June 8, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Zurich
  Purpose
To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.

Condition Intervention
Hyperkalemia Behavioral: decision support in potassium-inc. drug-drug-interactions

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions [ Time Frame: 1 year ]
    Rate of serum potassium monitoring intervals of < = 72 hours during potassium-increasing drug-drug-interactions in proportion to all serum potassium monitoring intervals during potassium-increasing drug-drug-interactions


Secondary Outcome Measures:
  • Frequency of hyperkalemia during potassium-increasing drug-drug-interactions [ Time Frame: 1 year ]
  • Frequency of potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia [ Time Frame: 1 year ]
  • Frequency of transfers to the ICU during potassium-increasing drug-drug-interactions in function of the serum potassium level [ Time Frame: 1 year ]
  • Frequency of death during potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia [ Time Frame: 1 year ]
  • Change in frequency distribution of serum potassium monitoring intervals [ Time Frame: 1 year ]
  • Response of physicians to the computer-based alerts and reminders [ Time Frame: 1 year ]

Enrollment: 3341
Study Start Date: January 2014
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: computer-based reminders and alerts
Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
Behavioral: decision support in potassium-inc. drug-drug-interactions
display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
No Intervention: no computer-based reminders or alerts
Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

Detailed Description:

The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours.

This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • in-patients treated with concurrent potassium-increasing drugs

Exclusion criteria:

  • outpatients; in-patients on wards without computerized physician order entry (i.e. patients treated in the ICU)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020317


Locations
Switzerland
University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Juerg Blaser, PhD, Prof University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics
  More Information

Publications:
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02020317     History of Changes
Other Study ID Numbers: FZMI-KEK-ZH-Nr. 2013
First Submitted: December 12, 2013
First Posted: December 24, 2013
Last Update Posted: June 8, 2015
Last Verified: June 2015

Keywords provided by University of Zurich:
drug interactions
Drug Monitoring
Potassium
Hyperkalemia

Additional relevant MeSH terms:
Hyperkalemia
Water-Electrolyte Imbalance
Metabolic Diseases